- Home
- SIGA vs AUTL Comparison
SIGA vs AUTL Comparison
Compare SIGA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | AUTL |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 752 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.0M | 407.2M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SIGA | AUTL |
|---|---|---|
| Price | $4.58 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 729.5K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 13.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | $224.81 | $53.96 |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $4.29 | $1.15 |
| 52 Week High | $9.62 | $2.70 |
Technical Indicators
Market Signals| Indicator | SIGA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 46.04 |
| Support Level | $4.29 | $1.22 |
| Resistance Level | $4.80 | $1.52 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 55.88 | 28.99 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.